$NSPX Morning gents. Combing through some of this stuff. " A pre-IND meeting for RT-AR-001 was held with the FDA in Q1 of 2021." That's great but it would have been nice to know that earlier? "The company expects to provide a further clinical update in the first half of 2022" Frustrating that the wait continues, but oh well.